Discovery of molecularly-informed therapeutic strategies for mature T-cell leukemias and lymphomas
Open Access
- 17 October 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5327-5340
Abstract
Mature T-cell leukemias and lymphomas (mTCL) comprise a clinically and genetically heterogeneous group of lymphoid malignancies. Most subtypes of peripheral T-cell lymphomas and leukemic T-cell malignancies show an aggressive clinical course and poor prognosis. Thus, these diseases urgently require novel therapeutic strategies. Taking advantage of recent progress deciphering the genetic basis of mTCL, we generated a comprehensive database of genetic alterations from 1825 patients with mTCL and utilized bioinformatic methodology developed to support treatment decisions in molecular tumor boards to identify novel potential therapeutics. Based on the results of this approach, we performed a systematic in vitro drug screen in molecularly characterized cell lines of mTCL to assess the activity of potential therapeutics. Of these, the cell cycle regulator WEE1 stood out as a novel therapeutic target in a genetically defined subgroup of mTCL. Indeed, WEE1 kinase inhibitors potently induced replication stress, premature mitotic entry, accumulation of DNA damage and induction of apoptosis in mTCL cell lines. Building on the single-agent activity of clinical grade WEE1 inhibitors, we next explored potential drug combination strategies through mechanistic studies. With this, we identified strong synergistic effects of combined WEE1 and JAK inhibition in genetically defined subtypes of mTCL, including primary patient samples of T-cell prolymphocytic leukemia. In summary, our study provides a comprehensive overview of the genetic landscape in mTCL and potential therapeutics in genetically defined subtypes. As such, we identified synergistic effects of dual WEE1 and JAK inhibition in cases with altered JAK/STAT signaling as a blueprint for clinical testing.Keywords
All Related Versions
This publication has 52 references indexed in Scilit:
- Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-RiskTP53Mutations in Head and Neck Cancer through Mitotic Arrest Followed by SenescenceMolecular Cancer Therapeutics, 2015
- ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomesBlood, 2014
- Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesJournal of Hematology & Oncology, 2014
- Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term SurvivorsJournal of Clinical Oncology, 2013
- Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study GroupBlood, 2010
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical OutcomesJournal of Clinical Oncology, 2008
- Histone H2AX Is Phosphorylated in an ATR-dependent Manner in Response to Replicational StressJournal of Biological Chemistry, 2001
- High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1HBlood, 2001
- dbSNP: the NCBI database of genetic variationNucleic Acids Research, 2001
- Inactivation of the ATM gene in T-cell prolymphocytic leukemias.1998